top of page
INNOVATORS
The progression of CRISPR technology would not be possible without the dedication of time, money, and effort from the following people/companies. Their work has not only established the foundation for the understanding of CRISPR but will continue to pave the way for new discoveries that can revolutionize the medical field.
Jennifer Doudna and Emmanuelle Charpentier
Jennifer Doudna (right) and Emmanuelle Charpentier (left) are widely accepted as the first to discover CRISPR-Cas9. Doudna is a biochemist who currently holds a position at UC Berkeley. Working at UC Berkeley, she and her team were the first to propose the use of the Cas9 protein along with CRISPR sequences as a method of gene editing. Charpentier essentially proved that the Cas9 protein could splice any DNA sequence with incredible precision. Because of their research and scientific contributions, the two scientists have been honored with and received many prestigious awards.
Intellia Therapeutics
Intellia Therapeutics is one of the many genome editing companies focused on utilizing CRISPR technology to develop cell therapy techniques. Working alongside Novartis, they are leading the way in expanding ex vivo (taking cells out of the body) applications of CRISPR. Intellia was founded in 2014 and uses "proprietary lipid nanoparticle delivery technology provides an innovative platform for safe and effective treatments".
GenEdit Therapeudics
GenEdit is a biotechnology company that strives to revolutionize gene editing using CRISPR technology. Their approach involves utilizing gene knockout and gene repair therapies in a more safe and efficient manner. GenEdit was launched in 2016 and has worked with UC Berkeley to develop its technology. An integral technology they've dedicated themselves to improving polymer-based nanoparticles, a delivery system that is able to hold CRISPR proteins and gene therapy molecules.
John Van der Oost
"Van der Oost is considered a pioneer of the 'CRISPR revolution' for his fundamental work on unravelling the mechanism of CRISPR-based immunity in bacteria, paving the way for developing CRISPR-mediated genome editing." His work was the first to demonstrate CRISPR's ability to target specific DNA sequences using RNA-guided mechanisms.
bottom of page